Company News: Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017

– Incurable HPV16+ solid tumors treated with therapeutic cancer vaccine plus checkpoint inhibitor

ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced the presentation of the results of a clinical Phase II trial initiated by MD Anderson Cancer Center in collaboration with ISA and Bristol-Myers Squibb (NCT02426892) at ESMO 2017 (September 8-12, 2017, Madrid, Spain). In the trial, cancer patients with HPV16+ incurable solid tumors received a combination of ISA’s synthetic long-peptide (SLP) HPV-16 vaccine ISA101 and nivolumab, a monoclonal antibody acting as a PD-1 checkpoint inhibitor.

An oral presentation of the results will be held by Bonnie Glisson MD, the Principle Investigator of the study, on Monday, September 11, 2017:

Proffered paper session “Immunotherapy of cancer”

Madrid Auditorium

11:45-12:00 “Nivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer”

The data will be based on abstract no. 1136O. The investigators intend to publish the data in a peer-reviewed journal later this year.